At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
Sorafenib (Nexavar, BAY43-9006)drug
Likely dose
Sorafenib (Nexavar, BAY43-9006) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Sorafenib (Nexavar, BAY43-9006) for Carcinoma, Renal Cell. Completed, enrolled 95 participants across 41 sites.
Detailed Summary
Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedJan 2008
Primary CompletionJun 2008
Study CompletionJul 2008
TodayJul 2026
First PostedJan 4, 2008
Enrollment StartDec 1, 2005
Primary CompletionJun 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.5 years ago
Interventions
Sorafenib (Nexavar, BAY43-9006)drug
Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally